Global Conjunctivitis Drugs Market Which Is Expected To Grow At A CAGR Of 3.1% From 2016 To 2022

Conjunctivitis is an eye condition characterized by inflammation of external white part and eyelids. Although this medical condition is caused due to various factors but bacterial and virus are most prominent causes accounting for more than 50% cases of conjunctivitis. The market for conjunctivitis drugs is facing stagnant growth in developed regions. Also, a number of patents which have expired such as Moxeza, Besivance, Vigamox, and Zymaxid have dampened the market growth. The market is further characterized by easy entry but high competition which has resulted into greater penetration by generics. The best strategy for firms is market development especially the Asian Pacific market which is poised to lead the growth of the global market in the near future. The market is further dampened by the better efficacy and broad spectrum of anti-bacterial drugs led by quinolones. Quinolones especially Fluoroquinolones has a dominant market share for conjunctivitis. The research pipeline is somewhat weak with many other classes of antibiotics exhibiting greater toxicity. Thus, quinolones have immensely raised the acceptable bar for newer drugs.

Get a sample report at https://www.marketresearchfuture.com/sample_request/2513 .

The market is chiefly driven by unmet needs in developing regions along with greater awareness and rising incomes in these regions. These reasons along with contagious nature of the disease along with rise of drug resistance also driving the market of other antibiotics which has greater toxicity such as macrolide class. Off label drug use is also one of the market drivers due to cheap generics and greater availability of these drugs.

Global Conjunctivitis Drugs market:

The global conjunctivitis drugs market has been evaluated to be growing and it is expected that it will touch high growth figures in future. The global conjunctivitis drugs market is expected to grow with CAGR of 3.1% in future. Market development and diversification into Asian Pacific market seems to have better strategy for the current situation.

Major participants of this market are: Akorn Pharmaceuticals, Alcon/ Novartis AG, Allergan Plc, Bausch & Lomb, Valeant Pharmaceuticals, Merck & Co. Inc., Actavis Plc., Pfizer Inc. and others.

Regional Analysis:

Depending on geographic region, conjunctivitis drugs market is segmented into four key regions: America, Europe, Asia Pacific, and Middle East & Africa. Globally, America is the largest market for conjunctivitis drugs followed by Europe. However, the developed regions market is stagnant and any future growth will be led by the developing regions especially Asia pacific region. The unmet drug needs and greater awareness are prime driver of the conjunctivitis drugs market. Greater exposure to allergens and infective agents is also driving the market’s growth.

Segmentation:

Global conjunctivitis drugs market has been segmented on the basis of conjunctivitis type which comprises of viral, bacterial, allergic and others types of conjunctivitis. On the basis of drug class; market is segmented into antibiotics (quinolones, aminoglycosides, macrolides and others), mast cell stabilizers, steroids and others. On the basis of route of administration; market is segmented into topical, oral and intra-vitreal. On the basis of end users; market is segmented into hospitals and self-administered.

Browse Complete Report at https://www.marketresearchfuture.com/reports/conjunctivitis-drugs-market-2513 .

Study Objectives Global Conjunctivitis Drugs Market:

To provide detail analysis of the market structure along with forecast for the next 7 years of various segments and sub-segments of the global conjunctivitis drugs market.
To provide insights about factors affecting the market growth.
To analyze the market based on various analyses which includes price analysis, supply chain analysis, Porters Five Force analysis etc.
To provide past and estimated future revenue of the market’s segments and sub-segments with respect to four main geographies and their countries- Americas, Europe, Asia-Pacific, and Middle East & Africa.
To provide country level analysis of the market with respect to the current market size and future growth prospect.
To provide country level analysis of the market for segments which includes by conjunctivitis type, by drug class, by route of administration, by end users and other sub segments.
To provide overview of key players and their strategic profiling in the market, comprehensively analyzing their core competencies and drawing a competitive landscape for the market
To track and analyze competitive developments such as joint ventures, strategic alliances, mergers and acquisitions, new product developments along with global research and developments.
Conjunctivitis, or pink eye, is inflammation of the outermost layer of the white part of the eye and the inner surface of the eyelid due to numerous causes the most common being bacterial infection. The condition is self-limiting, but in some cases results in kerato-conjunctivitis, which results in blurred vision. The viral and bacterial conjunctivitis results in highly infectious watery discharge which is extremely contagious.

The market for conjunctivitis is growing at a moderate rate. The growth factors for the growth of global conjunctivitis drugs market are rise in hygiene and awareness, growing expenditure on health, greater exposure to allergens and infective agents, the contagious nature of the disease etc. However the market is restrained by many factors such as the self-limiting nature of the disease, off label drug use, greater fragmentation of the market and penetration of generics etc. However the most important reason is loss of patents on a number of market leaders such as Moxeza, Besivance, Vigamox, and Zymaxid. The lack of specific treatment for allergic conjunctivitis and self-limiting and non-life threatening nature of the treatment also acts as a constraint.

About Market Research Future:
At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.

Contact us
Market Research Future
Maharashtra, India
+1 646 845 9312
Email: sales@Marketresearchfuture.Com

This release was published on openPR.